摘要The prognosis of small cell lung cancer is poor. Almost all patients have a tendency for tumor spreading to the whole body when they are diagnosed. Therefore, the combination of radiotherapy and chemotherapy is the main treatment, and surgical treatment is only implemented in a small number of limited patients. In recent years, there has been no obvious breakthrough in the treatment of small cell lung cancer, and the overall poor prognosis has not changed. With the development of medical technology, immune checkpoint inhibitors are gradually applied to the treatment of small-cell lung cancer, but the overall effect is limited. How to screen the beneficiary population to further improve the effect of immunotherapy is the key issue in the treatment of small-cell lung cancer.
Abstract：The prognosis of small cell lung cancer is poor. Almost all patients have a tendency for tumor spreading to the whole body when they are diagnosed. Therefore, the combination of radiotherapy and chemotherapy is the main treatment, and surgical treatment is only implemented in a small number of limited patients. In recent years, there has been no obvious breakthrough in the treatment of small cell lung cancer, and the overall poor prognosis has not changed. With the development of medical technology, immune checkpoint inhibitors are gradually applied to the treatment of small-cell lung cancer, but the overall effect is limited. How to screen the beneficiary population to further improve the effect of immunotherapy is the key issue in the treatment of small-cell lung cancer.
LI Yu-yan, LI Shan-shan, FAN Li, ZHANG Bin. Study on Immunotherapy-related Biomarkers of Small-cell Lung Cancer[J]. 中国生物医学工程学报(英文版）, 2022, 31(1): 27-32.
LI Yu-yan, LI Shan-shan, FAN Li, ZHANG Bin. Study on Immunotherapy-related Biomarkers of Small-cell Lung Cancer. Chinese Journal of Biomedical Engineering, 2022, 31(1): 27-32.
[1] Pennell NA, Arcila ME, Gandara DR, et al.Biomarker testing for patients with advanced non-small cell lung cancer[J].Real-World Issues and Tough Choices. Am Soc Clin Oncol Educ Book, 2019, 39:531-542. [2] Tsoukalas N, Kiakou M, Tsapakidis K, et al.PD-1 and PD-L1 as immunotherapy targetsandbio arkers in non-small cell lung cancer[J].J BUON, 2019, 24(3):883-888. [3] Leighl NB, Page RD, Raymond VM, et al.Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer[J].Clin Cancer Res, 2019, 25(15):4691-4700. [4] Yang Y, Wang Y.Present and future of efficacy biomarkers in immune checkpoint inhibitors of small cell lung cancer[J].Zhongguo Fei Ai Za Zhi, 2020, 23(10):897-903. [5] Zhang J, Zhou N, Lin A, et al.ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer[J].Cancer Immunol Immunother, 2021, 70(1):137-151. [6] Guven DC, Sahin TK, Dizdar O, et al.Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives[J].Biomark Med, 2020, 14(14):1383-1392. [7] Bhalla S, Doroshow DB, Hirsch FR.Predictive biomarkers for immune checkpoint inhibitors in advanced non-small cell lung cancer: current status and future directions[J].Cancer J, 2020, 26(6):507-516. [8] Kubo S, Kobayashi N, Somekawa K, et al.Identification of biomarkers for non-small-cell lung cancer patients treated with an immune checkpoint inhibitor[J].Anticancer Res, 2020, 40(7):3889-3896. [9] Jiang L, Dong H, Cao H, et al.Exosomes in pathogenesis, diagnosis, and treatment of alzheimer's disease[J].Med Sci Monit, 2019, 6(25):3329-3335.
